$TLRY

Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here’s Why TLRY Is Still Down 47% YTD

Tilray (TLRY) rose 6% to $4.75, Canopy Growth (CGC) 3% to $1.02, and Aurora Cannabis (ACB) 4% to $3.80, driven by Treasury buybacks lowering yields. Tilray is still down 47% YTD, despite diversification into non-cannabis segments. The cannabis sector's performance varies, with ETFs like MJ and MSOS showing mixed results.

Original reporting
Published Aug 19, 2026, 7:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 7:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here’s Why TLRY Is Still Down 47% YTD — source image
Decision brief

The 30-second read

$TLRYBullishMed
01

Why it matters

The policy lowers discount rates for speculative equities, prompting a rate‑driven rally in cannabis stocks.

02

Market read

Rate‑driven macro news sparked a brief rally in cannabis equities, offering short‑term trading opportunities.

03

What to watch

Tilray's diversification into beverages and medical extracts could provide longer‑term upside if execution succeeds, despite current rate‑driven move.

Relevance 7/10Novelty 6/10Timing: afternoon today

Background

Treasury announced it will double buybacks of 10‑ to 30‑year securities, pushing long‑end yields lower.

Company-level read

Ticker impact

$TLRYBullishMedium confidence
Context

Tilray shares rose 6% on Wednesday after the Treasury announced larger long‑dated debt buybacks, lowering yields and boosting speculative equities.

Expected impact

Potential further intraday gains if yields stay low; watch for reversal on earnings.

Evidence & confidence

The move is driven by macro rate action, not company fundamentals.

$CGCBullishMedium confidence
Context

Canopy Growth rose 3% as the broader cannabis complex benefited from the same Treasury‑driven rate decline.

Expected impact

Likely modest upside; monitor yield trends.

Evidence & confidence

Price move is indirect, tied to macro rather than company‑specific news.

$ACBBullishMedium confidence
Context

Aurora Cannabis gained 4% alongside Tilray and Canopy Growth on the Treasury yield‑drop driven rally.

Expected impact

Small upside potential; watch for earnings or sector news.

Evidence & confidence

Move stems from macro environment, not new company developments.

Market effects

Lower long‑end yields boost all speculative small‑cap and cannabis stocks, creating temporary sector‑wide rally.

U.S. Treasury policy influences North American cannabis equities and may spill into European markets with similar exposure.

Rate‑driven risk‑on sentiment can affect global risk assets, especially emerging‑market and commodity‑linked stocks.

Counterpoint

The yield‑driven rally may be a short‑term technical bounce; underlying fundamentals and large YTD declines suggest caution.

Key entities

  • Tilray Brands

    U.S.-listed cannabis and consumer products firm (NASDAQ:TLRY).

  • Canopy Growth

    Canadian cannabis producer (NASDAQ:CGC).

  • Aurora Cannabis

    Canadian cannabis producer (NASDAQ:ACB).

Related articles

$ACBHigh

Aurora Cannabis Furthers Global Medical Cannabis Growth with Accretive Acquisition of Internode Pharma Limited and HAP Pharma Limited, Expanding Distribution Access to the UK Medical Cannabis Market

Aurora Cannabis (ACB) acquired Internode Pharma and HAP Pharma to expand its UK medical cannabis market presence. The move aims to boost distribution, market share, and product supply. According to CEO Miguel Martin, the deal aligns with Aurora's strategy to grow in the international medical cannabis market.

$ACBMed

AURORA CANNABIS INC. URGES SHAREHOLDERS TO TAKE NO ACTION AT THIS TIME IN RESPECT TO THE UNSOLICITED TAKE-OVER BID BY CURALEAF HOLDINGS, INC.

Aurora Cannabis (TSX: ACB, NASDAQ: ACB) has urged shareholders to take no action regarding Curaleaf's (TSX: CURA, OTCQX: CURLF) unsolicited takeover bid of $4.00 per share, consisting of 0.3463 Curaleaf shares plus $0.75 in cash. Aurora's CEO, Miguel Martin, stated that Curaleaf's offer is designed to pressure shareholders into a short-term decision. Aurora has engaged with Curaleaf since June 2026 and plans to provide a comprehensive response to shareholders in due course.

$ACBHighAI 9/10

Curaleaf’s Hostile Bid For Aurora Is Official

Curaleaf has made a public hostile bid for Aurora, offering $4 per share, a 45% premium on Aurora's 30-day average. Curaleaf aims to create a $3B combined company with cost synergies and access to EU medical cannabis markets. Aurora's board is reviewing the deal. Shares of both companies moved on the news.

$CURLFHighAI 9/10

Curaleaf launches US$260 million takeover bid for Canadian producer Aurora Cannabis

Curaleaf Holdings launched a takeover bid for Aurora Cannabis valuing it at about US$260 million, a week after its initial proposal, according to Curaleaf and Reuters. Aurora shareholders would receive 0.3463 Curaleaf shares and $0.75 cash per share, about $4 total, with a cap tied to Curaleaf’s stock. The offer runs until Dec. 1 pending approvals and majority support.

$ACBHighAI 9/10

Curaleaf launches $260-million takeover bid for Aurora Cannabis

Curaleaf Holdings launched a takeover bid for Aurora Cannabis valuing it at about US$260 million. Aurora shareholders would receive 0.3463 Curaleaf shares plus $0.75 cash per share, totaling $4 per share, with a cap at $5 if Curaleaf stock rises. The offer runs until Dec. 1, pending approvals and majority support. Aurora shares rose 3% early.